Island Secures Uganda Approval for Galidesivir Use in Ebola Outbreak
Closing price · 2026-10-26: $0.310 · -4.62%
Island Pharmaceuticals secured government, regulatory and ethics approvals for compassionate Galidesivir use during Uganda’s Bundibugyo Ebola outbreak, creating an opportunity to collect prospective human clinical data. The company also advanced its Marburg development program through a Texas Biomedical dose-optimisation study agreement and access to natural-history data, while GMP manufacturing has commenced and a USAMRIID animal study is being prepared.